Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91

Yoshikazu Sugimoto, Satomi Tsukahara, Shigeo Sato, Mutsumi Suzuki, Hiroyuki Nunoi, Harry L. Malech, Michael M. Gottesman, Takashi Tsuruo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Retroviral transduction of human hematopoietic stem cells is an attractive strategy in gene therapy; however, transduction efficiency and duration of transgene expression may not be satisfactory in current protocols. Co-expression of a human multidrug resistance gene (MDR1) with a therapeutic gene affords selectable growth advantage to genetically modified cells. Methods: A bicistronic retrovirus vector, Ha-MDR-IRES-gp91, was constructed for the co-expression of MDR1 and gp91, a gene responsible for X-linked chronic granulomatous disease (X-CGD). Drug-selected co-expression of P-glycoprotein and gp91 was evaluated in transduced cells. Results: Epstein-Barr virus-transformed B cells from X-CGD patients transduced with Ha-MDR-IRES-gp91 co-expressed human P-glycoprotein and gp91, and acquired superoxide-generating activity. Human CD34-positive cells from an X-CGD patient were transduced with Ha-MDR-IRES-gp91 and subsequently treated with 2 ng/ml vincristine. After 13 days, 20% of Ha-MDR-IRES-gp91-transduced cells were P-glycoprotein- and gp91-positive by FACS analysis. The superoxide-generating activity of the transduced population was 27% of that of normal cells. Mice transplanted with Ha-MDR-IRES-gp91-transduced bone marrow cells showed co-expression of P-glycoprotein and gp91 in peripheral blood mononuclear cells. By administering paclitaxel, the proportions of P-glycoprotein- and gp91-positive cells were increased in all the four mice examined. When mice transplanted with Ha-MDR-IRES-gp91-transduced cells were repeatedly administered paclitaxel, the ratios of P-glycoprotein- and gp91-positive cells were maintained for over 1 year. Conclusions: These results suggest that MDR1-bicistronic vectors may be useful to select the transduced hematopoietic cells in vivo. This may lead to the sustained expression of transgenes in the blood cells of patients treated with stem cell gene therapy.

Original languageEnglish
Pages (from-to)366-376
Number of pages11
JournalJournal of Gene Medicine
Volume5
Issue number5
DOIs
Publication statusPublished - 2003 May
Externally publishedYes

Fingerprint

P-Glycoprotein
Retroviridae
Pharmaceutical Preparations
Chronic Granulomatous Disease
Paclitaxel
Transgenes
Superoxides
Genetic Therapy
Blood Cells
MDR Genes
Vincristine
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Human Herpesvirus 4
Bone Marrow Cells
Genes
B-Lymphocytes
Stem Cells
Growth

Keywords

  • Bicistronic retrovirus vector
  • Chronic granulomatous disease
  • Drug resistance
  • Gene therapy
  • Hematopoietic stem cell
  • P-glycoprotein

ASJC Scopus subject areas

  • Genetics

Cite this

Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91. / Sugimoto, Yoshikazu; Tsukahara, Satomi; Sato, Shigeo; Suzuki, Mutsumi; Nunoi, Hiroyuki; Malech, Harry L.; Gottesman, Michael M.; Tsuruo, Takashi.

In: Journal of Gene Medicine, Vol. 5, No. 5, 05.2003, p. 366-376.

Research output: Contribution to journalArticle

Sugimoto, Yoshikazu ; Tsukahara, Satomi ; Sato, Shigeo ; Suzuki, Mutsumi ; Nunoi, Hiroyuki ; Malech, Harry L. ; Gottesman, Michael M. ; Tsuruo, Takashi. / Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91. In: Journal of Gene Medicine. 2003 ; Vol. 5, No. 5. pp. 366-376.
@article{ebe46d3bd2f34faf9236245310edb16e,
title = "Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91",
abstract = "Background: Retroviral transduction of human hematopoietic stem cells is an attractive strategy in gene therapy; however, transduction efficiency and duration of transgene expression may not be satisfactory in current protocols. Co-expression of a human multidrug resistance gene (MDR1) with a therapeutic gene affords selectable growth advantage to genetically modified cells. Methods: A bicistronic retrovirus vector, Ha-MDR-IRES-gp91, was constructed for the co-expression of MDR1 and gp91, a gene responsible for X-linked chronic granulomatous disease (X-CGD). Drug-selected co-expression of P-glycoprotein and gp91 was evaluated in transduced cells. Results: Epstein-Barr virus-transformed B cells from X-CGD patients transduced with Ha-MDR-IRES-gp91 co-expressed human P-glycoprotein and gp91, and acquired superoxide-generating activity. Human CD34-positive cells from an X-CGD patient were transduced with Ha-MDR-IRES-gp91 and subsequently treated with 2 ng/ml vincristine. After 13 days, 20{\%} of Ha-MDR-IRES-gp91-transduced cells were P-glycoprotein- and gp91-positive by FACS analysis. The superoxide-generating activity of the transduced population was 27{\%} of that of normal cells. Mice transplanted with Ha-MDR-IRES-gp91-transduced bone marrow cells showed co-expression of P-glycoprotein and gp91 in peripheral blood mononuclear cells. By administering paclitaxel, the proportions of P-glycoprotein- and gp91-positive cells were increased in all the four mice examined. When mice transplanted with Ha-MDR-IRES-gp91-transduced cells were repeatedly administered paclitaxel, the ratios of P-glycoprotein- and gp91-positive cells were maintained for over 1 year. Conclusions: These results suggest that MDR1-bicistronic vectors may be useful to select the transduced hematopoietic cells in vivo. This may lead to the sustained expression of transgenes in the blood cells of patients treated with stem cell gene therapy.",
keywords = "Bicistronic retrovirus vector, Chronic granulomatous disease, Drug resistance, Gene therapy, Hematopoietic stem cell, P-glycoprotein",
author = "Yoshikazu Sugimoto and Satomi Tsukahara and Shigeo Sato and Mutsumi Suzuki and Hiroyuki Nunoi and Malech, {Harry L.} and Gottesman, {Michael M.} and Takashi Tsuruo",
year = "2003",
month = "5",
doi = "10.1002/jgm.362",
language = "English",
volume = "5",
pages = "366--376",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91

AU - Sugimoto, Yoshikazu

AU - Tsukahara, Satomi

AU - Sato, Shigeo

AU - Suzuki, Mutsumi

AU - Nunoi, Hiroyuki

AU - Malech, Harry L.

AU - Gottesman, Michael M.

AU - Tsuruo, Takashi

PY - 2003/5

Y1 - 2003/5

N2 - Background: Retroviral transduction of human hematopoietic stem cells is an attractive strategy in gene therapy; however, transduction efficiency and duration of transgene expression may not be satisfactory in current protocols. Co-expression of a human multidrug resistance gene (MDR1) with a therapeutic gene affords selectable growth advantage to genetically modified cells. Methods: A bicistronic retrovirus vector, Ha-MDR-IRES-gp91, was constructed for the co-expression of MDR1 and gp91, a gene responsible for X-linked chronic granulomatous disease (X-CGD). Drug-selected co-expression of P-glycoprotein and gp91 was evaluated in transduced cells. Results: Epstein-Barr virus-transformed B cells from X-CGD patients transduced with Ha-MDR-IRES-gp91 co-expressed human P-glycoprotein and gp91, and acquired superoxide-generating activity. Human CD34-positive cells from an X-CGD patient were transduced with Ha-MDR-IRES-gp91 and subsequently treated with 2 ng/ml vincristine. After 13 days, 20% of Ha-MDR-IRES-gp91-transduced cells were P-glycoprotein- and gp91-positive by FACS analysis. The superoxide-generating activity of the transduced population was 27% of that of normal cells. Mice transplanted with Ha-MDR-IRES-gp91-transduced bone marrow cells showed co-expression of P-glycoprotein and gp91 in peripheral blood mononuclear cells. By administering paclitaxel, the proportions of P-glycoprotein- and gp91-positive cells were increased in all the four mice examined. When mice transplanted with Ha-MDR-IRES-gp91-transduced cells were repeatedly administered paclitaxel, the ratios of P-glycoprotein- and gp91-positive cells were maintained for over 1 year. Conclusions: These results suggest that MDR1-bicistronic vectors may be useful to select the transduced hematopoietic cells in vivo. This may lead to the sustained expression of transgenes in the blood cells of patients treated with stem cell gene therapy.

AB - Background: Retroviral transduction of human hematopoietic stem cells is an attractive strategy in gene therapy; however, transduction efficiency and duration of transgene expression may not be satisfactory in current protocols. Co-expression of a human multidrug resistance gene (MDR1) with a therapeutic gene affords selectable growth advantage to genetically modified cells. Methods: A bicistronic retrovirus vector, Ha-MDR-IRES-gp91, was constructed for the co-expression of MDR1 and gp91, a gene responsible for X-linked chronic granulomatous disease (X-CGD). Drug-selected co-expression of P-glycoprotein and gp91 was evaluated in transduced cells. Results: Epstein-Barr virus-transformed B cells from X-CGD patients transduced with Ha-MDR-IRES-gp91 co-expressed human P-glycoprotein and gp91, and acquired superoxide-generating activity. Human CD34-positive cells from an X-CGD patient were transduced with Ha-MDR-IRES-gp91 and subsequently treated with 2 ng/ml vincristine. After 13 days, 20% of Ha-MDR-IRES-gp91-transduced cells were P-glycoprotein- and gp91-positive by FACS analysis. The superoxide-generating activity of the transduced population was 27% of that of normal cells. Mice transplanted with Ha-MDR-IRES-gp91-transduced bone marrow cells showed co-expression of P-glycoprotein and gp91 in peripheral blood mononuclear cells. By administering paclitaxel, the proportions of P-glycoprotein- and gp91-positive cells were increased in all the four mice examined. When mice transplanted with Ha-MDR-IRES-gp91-transduced cells were repeatedly administered paclitaxel, the ratios of P-glycoprotein- and gp91-positive cells were maintained for over 1 year. Conclusions: These results suggest that MDR1-bicistronic vectors may be useful to select the transduced hematopoietic cells in vivo. This may lead to the sustained expression of transgenes in the blood cells of patients treated with stem cell gene therapy.

KW - Bicistronic retrovirus vector

KW - Chronic granulomatous disease

KW - Drug resistance

KW - Gene therapy

KW - Hematopoietic stem cell

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=1542466885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542466885&partnerID=8YFLogxK

U2 - 10.1002/jgm.362

DO - 10.1002/jgm.362

M3 - Article

C2 - 12731085

AN - SCOPUS:1542466885

VL - 5

SP - 366

EP - 376

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 5

ER -